LMTK2 Inhibits Metastasis of Colon Cancer Cells Through p38 MAPK
Cancer Science · 2026-11 · 117 (11) · 3039-3051
DOI: 10.1111/cas.70490 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 04.08.2026. Verfasst von Jie Lun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao Cancer Institute, Qingdao, China. Hauptthemen laut MEDLINE: p38 Mitogen-Activated Protein Kinases, Colonic Neoplasms, Protein Serine-Threonine Kinases, Membrane Proteins. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Shandong Provincial Medical and Health Science and Technology Project, Natural Science Foundation of Qingdao.
Abstract (Originalsprache)
Metastasis is the leading cause of death in patients with colon cancer. Although Lemur tyrosine kinase 2 (LMTK2) has been implicated in cell proliferation, its role in metastasis is unclear. In this study, we found that low LMTK2 expression correlates with metastatic status (M1 stage) and a higher metastasis rate in a large colon cancer cohort. Additionally, LMTK2 expression is negatively correlated with pro‐metastatic genes and positively correlated with metastasis suppressors, a pattern that was validated in 50 clinical colon cancer specimens. Functional studies demonstrated that LMTK2 potently inhibits cell migration and invasion in vitro and suppresses metastasis in a mouse model in vivo. Mechanistically, LMTK2 disrupts the interaction between p38 MAPK and its upstream kinases MKK3/6, thereby inhibiting p38 activation and subsequent cell migration and invasion. Notably, the kinase‐deficient LMTK2 (K168R) mutant also suppresses p38 phosphorylation and impedes cell migration and invasion. These results uncover a novel anti‐metastatic function of LMTK2, which acts through inhibition of p38 independently of its kinase activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao Cancer Institute, Qingdao, China.
- School of Pharmacy, Qingdao University, Qingdao, China.
- Institute for Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.
- Central Laboratory, Qingdao Municipal Hospital, Qingdao, China.
ORCID-Profile: Mengchao Yu
Förderung
- National Natural Science Foundation of China
- Shandong Provincial Medical and Health Science and Technology Project
- Natural Science Foundation of Qingdao
- Ministry of Science and Technology of China
- Natural Science Foundation of Qingdao Municipality
Zitieren
APA
Lun, J., Zhang, J., Xu, J., Jing, L., Qin, Y., Fang, J., & Yu, M. (2026). LMTK2 Inhibits Metastasis of Colon Cancer Cells Through p38 MAPK. Cancer Science, 117(11), 3039-3051. https://doi.org/10.1111/cas.70490
Vancouver
Lun J, Zhang J, Xu J, Jing L, Qin Y, Fang J, et al. LMTK2 Inhibits Metastasis of Colon Cancer Cells Through p38 MAPK. Cancer Science. 2026;117(11):3039-3051. doi:10.1111/cas.70490
BibTeX
@article{Lun2026,
author = {Lun, Jie and Zhang, Jinzhao and Xu, Jianxin and Jing, Liyuan and Qin, Yanqing and Fang, Jing and Yu, Mengchao},
title = {LMTK2 Inhibits Metastasis of Colon Cancer Cells Through p38 MAPK},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {11},
pages = {3039--3051},
doi = {10.1111/cas.70490}
}
EUVIMED